1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Drugs In Development, 2022, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 9, 3, 1 and 4 respectively.
Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Angina (Angina Pectoris) - Overview
- Angina (Angina Pectoris) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Angina (Angina Pectoris) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
- Angionetics Inc
- Arbor Pharmaceuticals LLC
- AstraZeneca Plc
- Caladrius Biosciences Inc
- Chong Kun Dang Holdings Corp
- Coeurative Inc
- Eight Plus One Pharmaceutical Co Ltd
- G. Pohl-Boskamp GmbH & Co KG
- Hemostemix Inc
- Imbria Pharmaceuticals Inc
- Innovative Pharmacology Research
- Jiangsu Hengrui Medicine Co Ltd
- Kuhnil Pharmaceutical Co Ltd
- Merck & Co Inc
- Milestone Pharmaceuticals Inc
- Signal Pharma Ltd
- Trizell Ltd
- TSH Biopharm Corporation Ltd
- VasThera Co Ltd
- XyloCor Therapeutics Inc
- Angina (Angina Pectoris) - Drug Profiles
- ACP-01 - Drug Profile
- Product Description
- Mechanism Of Action
- alferminogene tadenovec - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AR-36 - Drug Profile
- Product Description
- Mechanism Of Action
- BJY-802 - Drug Profile
- Product Description
- Mechanism Of Action
- CKD-385 - Drug Profile
- Product Description
- Mechanism Of Action
- CR-0305 - Drug Profile
- Product Description
- Mechanism Of Action
- EG-011 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- encoberminogene rezmadenovec - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- etripamil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GRS - Drug Profile
- Product Description
- Mechanism Of Action
- ivabradine hydrochloride SR - Drug Profile
- Product Description
- Mechanism Of Action
- KI-1007 - Drug Profile
- Product Description
- Mechanism Of Action
- ninerafaxstat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nitroglycerin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ranolazine ER - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Angina - Drug Profile
- Product Description
- Mechanism Of Action
- tirofiban hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VTA-02 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Xowna - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- zibotentan - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Angina (Angina Pectoris) - Dormant Projects
- Angina (Angina Pectoris) - Discontinued Products
- Angina (Angina Pectoris) - Product Development Milestones
- Featured News & Press Releases
- May 23, 2022: Caladrius Biosciences provides update on phase 2b FREEDOM Trial of XOWNA in Coronary Microvascular Dysfunction
- May 10, 2022: Hemostemix announces its intellectual property is back home
- Apr 12, 2022: Hemostemix announces intellectual property due diligence and data audit completed
- Jan 19, 2021: Caladrius Biosciences treats first patient in the phase 2b FREEDOM trial of CLBS16 for the treatment of coronary microvascular dysfunction
- May 14, 2020: Caladrius Biosciences reports positive full results for CLBS16 from the ESCaPE-CMD trial at SCAI 2020 Scientific Sessions
- May 06, 2020: Caladrius Biosciences announces presentation of full results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
- Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019
- Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences
- Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Coronary Microvascular Dysfunction
- Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
- Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
- Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
- Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
- Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
- Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Angina (Angina Pectoris), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Angina (Angina Pectoris) - Pipeline by Angionetics Inc, 2022
- Angina (Angina Pectoris) - Pipeline by Arbor Pharmaceuticals LLC, 2022
- Angina (Angina Pectoris) - Pipeline by AstraZeneca Plc, 2022
- Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, 2022
- Angina (Angina Pectoris) - Pipeline by Chong Kun Dang Holdings Corp, 2022
- Angina (Angina Pectoris) - Pipeline by Coeurative Inc, 2022
- Angina (Angina Pectoris) - Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022
- Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, 2022
- Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, 2022
- Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, 2022
- Angina (Angina Pectoris) - Pipeline by Innovative Pharmacology Research, 2022
- Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
- Angina (Angina Pectoris) - Pipeline by Merck & Co Inc, 2022
- Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, 2022
- Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, 2022
- Angina (Angina Pectoris) - Pipeline by Trizell Ltd, 2022
- Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, 2022
- Angina (Angina Pectoris) - Pipeline by VasThera Co Ltd, 2022
- Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, 2022
- Angina (Angina Pectoris) - Dormant Projects, 2022
- Angina (Angina Pectoris) - Dormant Projects, 2022 (Contd..1)
- Angina (Angina Pectoris) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Angina (Angina Pectoris), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Angionetics Inc
- Arbor Pharmaceuticals LLC
- AstraZeneca Plc
- Caladrius Biosciences Inc
- Chong Kun Dang Holdings Corp
- Coeurative Inc
- Eight Plus One Pharmaceutical Co Ltd
- G. Pohl-Boskamp GmbH & Co KG
- Hemostemix Inc
- Imbria Pharmaceuticals Inc
- Innovative Pharmacology Research
- Jiangsu Hengrui Medicine Co Ltd
- Kuhnil Pharmaceutical Co Ltd
- Merck & Co Inc
- Milestone Pharmaceuticals Inc
- Signal Pharma Ltd
- Trizell Ltd
- TSH Biopharm Corporation Ltd
- VasThera Co Ltd
- XyloCor Therapeutics Inc
